Finanzen von Ultragenyx Pharmaceutical Inc (RARE)RAREUltragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. (RARE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Crysvita royalty revenue, accounting for 47.7% of total sales, equivalent to $102.00M. Other significant revenue streams include Crysvita and Dojolvi. Understanding this composition is critical for investors evaluating how RARE navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Ultragenyx Pharmaceutical Inc. maintains a gross margin of 84.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -35.05%, while the net margin is -42.99%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RARE converts its operational activities into shareholder value.

In the context of the broader market, RARE competes directly with industry leaders such as SUPN and PBH. With a market capitalization of $2.59B, it holds a significant position in the sector. When comparing efficiency, RARE's gross margin of 84.11% stands against SUPN's 73.07% and PBH's 49.11%. Such benchmarking helps identify whether Ultragenyx Pharmaceutical Inc. is trading at a premium or discount relative to its financial performance.

Ultragenyx reported a gross margin of 84.11% in Q2 2026, indicating strong profitability potential. However, the company has been experiencing significant net losses, with a net income of -92 million USD in the latest quarter.